3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
7
Breast Neoplasms
4
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Colorectal Neoplasms
2
Uveal Melanoma
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tobacco Use Disorder
1
Substance-Related Disorders
1
Smoking
1
Patient Acceptance of Health Care
1
Motor Activity
1
Lymphoma
1
Lung Cancer Screening
1
Leukemia
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Depression
1
Death
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Cancer Patients
1
Acquired Immunodeficiency Syndrome
1
Interventions
Gemcitabine
56
pembrolizumab
50
Cisplatin
43
Magnetic Resonance Spectroscopy
27
enfortumab vedotin
22
Specimen Handling
22
Nivolumab
22
Cystectomy
18
durvalumab
16
Carboplatin
16
avelumab
15
Mitomycin
14
atezolizumab
13
Docetaxel
13
Cystoscopy
12
Fluorouracil
11
Radiation
9
Transurethral Resection of Bladder
8
Radiotherapy
8
Ipilimumab
8
sacituzumab govitecan
7
Standard of Care
7
Radiosurgery
7
Paclitaxel
7
Immunoglobulin G
7
Disulfides
7
erdafitinib
6
cemiplimab
6
Surveys and Questionnaires
6
Surgical Procedures, Operative
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Focus Groups
×
1 year
×
Clear all
NCT07091565
2025-08-03
SPARC
King's College London
Enrolling by invitation
60 enrolled